Design of enhanced binding antigen peptides using Frederick National Laboratory for Cancer Research Gaussian process regression **KIDGE** David R. Bell¹ and Serena H. Chen² National Laboratory ¹Frederick National Laboratory for Cancer Research ENERGY ²Oak Ridge National Laboratory

Background: In biologics drug discovery, one objective is to design and optimize biological therapeutics such as antibodies and antigen-specific immunotherapies for enhanced binding. A naïve way of optimizing protein binding is to mutate protein residues and determine the difference in binding affinity. This mutagenesis technique is costly and often leads to decreased affinity mutants. Here, we develop a way to minimize this cost and predict enhanced affinity mutants from minimal prior data.

Methods: Use Gaussian process (GP) regression across residue volume and hydrophobicity to predict mutant peptide-MHCII binding affinities from a small residue subset Experimental or theoretical



mutant affinity subset: 🛧 Gin, Gly, Ile, Thr, Trp GP regression of volume, hydrophobicity Mutant affinity prediction: • Ala, Asn, Cys, Leu, Met, Phe, Pro, Ser, Tyr, Val

GP regression workflow, focusing on

affinity prediction of neutral residues

MHCII-antigen peptide system. We focus on predicting mutant antigen binding affinities



GP regression accurately predicts mutant binding affinities

Computational Dataset from FEP calculations



R² coefficient of determination and errors for prediction of Free Energy Perturbation (FEP) affinities





GP regression-predicted affinity landscapes for (left) a 6residue subset and (right) all neutral residues based on an FEP-computed affinity dataset

Experimental Dataset from IEDB



R² coefficient of determination and errors for prediction of experimental affinities from the Immune Epitope Database (IEDB) (n=167 antigen test set with all 20 residue mutations)

Residue volume and hydrophobicity are powerful 2-D descriptors, outperforming 5-D principal components



GP regression accuracy increases for buried residues without competing conformations

lle

Met

His

Glu

Glr

150

신신G (kcal/mol)

Val Leu

Phe

200

Tr



GP regression accuracy improves when applied to point mutations of buried antigen 'anchor' residues and mutant systems that do not undergo MHCantigen conformational changes, so-called 'register-constrained'

Blosum62 (n=10 dimensions) and outperform T-scale (n=5 dimensions) features for small residue subsets

Discussion: This GP regression method predicts mutant binding affinities with uncertainty information in real-time across a visually- and physically-interpretable feature space. This approach is well-suited for active learning workflows where the optimal mutant residue is predicted and optimized from binding affinity knowledge of a small residue subset.

References:

- Bell, D.R., Chen, S.H. https://doi.org/10.1021/acs.jcim.1c00458
- 2 Hie, B., et al. https://doi.org/10.1016/j.cels.2020.09.007

Contact Information: david.bell@nih.gov, chens@ornl.gov

Acknowledgements: The authors would like to thank Leili Zhang, Guojing Cong, Giacomo Domeniconi, Chih-Chieh Yang, Ruhong Zhou, Jeffrey K Weber, and Sangyun Lee for insightful discussions. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.